Melanoma | PRIME Journal

SkinCeuticals, CeraVe, La Roche-Posay & Melanoma Research Alliance Launch Three-Year Partnership in the United States

May 4, 2020 | News | 0 |

An annual Team Science Award will be Issued to Researchers Studying Artificial Intelligence (AI)...

Novartis receives FDA approval of Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600-mutant melanoma

May 14, 2018 | News | 0 |

Novartis announced that the US Food and Drug Administration (FDA) has approved Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) for...

Promising new drug stops spread of melanoma by 90 percent

Jan 6, 2017 | News | 0 |

Michigan State University researchers have discovered that a chemical compound, and potential new drug, reduces the spread of melanoma cells...

Cliff Rosendahl: Diagnosing melanoma

Mar 23, 2016 | News, Dermatology | 0 |

(more…)

ASDS: Costs to treat non-melanoma skin cancers in line with costs for other cancers

Nov 17, 2014 | News | 0 |

While skin cancer remains a growing major public health problem, a recent study focusing instead on the disease’s economic impact (more…)

Pain and itch may be signs of skin cancer

Jul 24, 2014 | 0 |

Asking patients if a suspicious skin lesion is painful or itchy may help doctors decide whether the spot is likely (more…)

Melanoma recurs after 10 years in 6% of patients

Jul 22, 2013 | 0 |

Recurrence of melanoma 10 or more years after initial treatment is more common than previously thought, occurring in more than...

Editorial: SPOT Skin Cancer

Mar 19, 2013 | 0 |

Coco Chanel is often accredited with making the sun tan popular in the 1920s. Prior to that, having tanned skinned signified (more…)

Tag: Melanoma

SkinCeuticals, CeraVe, La Roche-Posay & Melanoma Research Alliance Launch Three-Year Partnership in the United States

Novartis receives FDA approval of Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600-mutant melanoma

Promising new drug stops spread of melanoma by 90 percent

Cliff Rosendahl: Diagnosing melanoma

ASDS: Costs to treat non-melanoma skin cancers in line with costs for other cancers

Pain and itch may be signs of skin cancer

Melanoma recurs after 10 years in 6% of patients

Editorial: SPOT Skin Cancer

Search

Recent Posts

Login Status

Upcoming Events

AMWC 2021 – The Hybrid Edition

AMWC LATIN AMERICA 2021

AMWC China 2021

Recent Tweets

Categories